Cantor Fitzgerald analyst Sarah James raised the firm’s price target on HCA Healthcare (HCA) to $525 from $444 and keeps an Overweight rating on the shares. HCA Heatlhcare’s operational excellence persists as it paves an achievable path to 2025 guidance and an optimistic 2026 outlook, the analyst tells investors in a research note. Preliminary 2026 commentary suggests fundamentals are well-intact, the firm adds.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare price target raised to $500 from $400 at Oppenheimer
- HCA Healthcare price target raised to $505 from $475 at Mizuho
- HCA Healthcare: Hold Rating Amid Limited Growth Potential and Policy Uncertainties
- HCA Healthcare price target raised to $475 from $465 at KeyBanc
- HCA Healthcare: Strong Financial Performance and Strategic Growth Drive Buy Rating